The Latest Analyst Ratings for Bellerophon Therapeutics
HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target
Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35
HC Wainwright & Co. Reiterates Buy on Bellerophon Therapeutics, Maintains $30 Price Target
Watching Baylor BioSciences; Brookline Capital Reiterates Buy Rating, Sets $19 Price Target
No Data